Company Overview and News

 
Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

3h globenewswire
-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae --
Upvote Downvote

8
AKAO / Achaogen, Inc. DEF 14A

2018-04-18 sec.gov
akao-def14a_20180605.htm UNITED STATES
Upvote Downvote

12
AKAO / Achaogen, Inc. DEFA14A

2018-04-18 sec.gov
akao-defa14a_20180605.htm UNITED STATES
Upvote Downvote

4
Biotech Forum: The Week Ahead

2018-04-16 seekingalpha
The biotech sector had a solid showing in the week just past and rose with the overall market.
Upvote Downvote

1
Specialty Report On Infectious Disease: Unlocking The Upcoming Binary Event Of Achaogen And Value Of Melinta

2018-04-16 seekingalpha
Achaogen already posted robust phase 3 data for plazomicin (non-inferiority and superiority) as a treatment for resistant infection. The PDUFA date of plazomicin was set for June 25, 2018.
Upvote Downvote

3
Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

2018-04-10 globenewswire
-- Study findings support the potential for plazomicin to address difficult-to-treat infections, including those caused by carbapenem-resistant Enterobacteriaceae --
Upvote Downvote

2
ArGen-X started at buy with $125 stock price target at SunTrust RH

2018-04-09 marketwatch
Small- and mid-cap biotech stocks have displayed usual first quarter resilience, setting the stage for second quarter upside.
Upvote Downvote

7
Achaogen: Contrarian Play At An Inflection Point

2018-03-22 seekingalpha
Investing in antibiotics for high-need indications is a deeply contrarian move, motivated by shifting epidemiological and pharmacoeconomic dynamics.
Upvote Downvote

1
U.S. Biotech/Pharma Sector Daily Observations Letter: March 21, 2018

2018-03-22 seekingalpha
The broad U.S. biotechnology sector showed some signs of a rebound today, outperforming the broad market indexes. Fed raised the interest rate by 0.25% as expected.
Upvote Downvote

3
Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin

2018-03-21 globenewswire
SOUTH SAN FRANCISCO, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has planned a meeting to review the Company's New Drug Application (NDA) for plazomicin for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and bloodstream infections (BSI) due to certain Enterobacteriaceae in patients who have limited or no alternative treatment option.
Upvote Downvote

4
AKAO / Achaogen, Inc. / DUGGAN ROBERT W - AMENDMENT NO. 3 TO THE SCHEDULE 13D (Activist Investment)

2018-03-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
Upvote Downvote

4
AKAO / Achaogen, Inc. / DUGGAN ROBERT W - AMENDMENT NO. 3 TO THE SCHEDULE 13D (Activist Investment)

2018-03-14 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101)
Upvote Downvote

4
Oh, Hi March

2018-03-06 seekingalpha
As we wait for the much anticipated (and highly strenuous) data from Marinus (MRNS) we shouldn't forget that Cidara (CDTX) still has data to come out - reportedly by the end of this month (we previously anticipated much earlier). Cidara's price has behaved much more stably than Marinus, and we see this as a good sign - the market for buyers and sellers is relatively even and nobody is playing games with the stock (intentional or not).
Upvote Downvote

5
Your Daily Pharma Scoop: Celgene Setback, Valeant Results, Synergy Sells Rights

2018-03-01 seekingalpha
Our Marketplace service, the Total Pharma Tracker, is going to offer a one-week free trial starting March 1. Click here to register. The offer lasts until March 7; so, you know, hurry.
Upvote Downvote

AKAO : Achaogen Stock Analysis and Research Report

2017-11-08 - Asif

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments against multi-drug resistant (“MDR”) gram-negative infections. Achaogen is researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (“cUTI”), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (“CRE”). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action” and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics. On December 12, 2016, the company announced positive data from its two Phase 3 clinical trials for plazomicin. The firs...

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 004449104